File photo
File photo
The state-run alternate care site in El Paso is able to provide outpatient treatment with bamlanivimabl, the Eli Lilly and Co. monoclonal antibody therapy for the treatment of those with COVID-19.
The Texas Division Of Emergency Management established the bamlanivimabl infusion wing of the alternate care site with an initial 1,000 doses provided by the U.S. Department of Health and Human Services, according to a press release. The El Paso site was picked to participate in a pilot program.
"The establishment of the bamlanivimab infusion wing at El Paso's alternate care site is crucial to keeping hospitalizations down and protecting at-risk Texans in the community," Gov. Greg Abbott said. "I thank HHS for supporting our efforts by supplying the State of Texas with this shipment of bamlanivimab for the pilot program. We will continue to ensure that this life-saving antibody therapy is available for Texans who need it most."
Alerts Sign-up